Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
A new obesity-medicine finding complicates a common assumption about GLP-1 weight-loss drugs: losing weight does not necessarily mean people start moving more.
Research presented at ENDO 2026 analysed adults with obesity who began GLP-1 receptor agonist medication. The study used the NIH All of Us Research Program, combining electronic health records with Fitbit activity data.
The analysis began with 1,950 adults who started GLP-1 treatment. Of those, 753 had enough wearable-device data for the final analysis. Most participants were women, and the average age was 52.7 years.
The numbers
Average daily steps fell from 5,047 to 4,487 after treatment began. Minutes of moderate-to-vigorous physical activity also dropped, from 28 minutes per day to 22 minutes per day.
The largest decreases were seen in men and in people reporting joint or muscle pain. Age, heart failure and prior stroke did not change the overall pattern, according to the Endocrine Society summary.
Why this matters now
GLP-1 drugs such as semaglutide and tirzepatide have become central to obesity treatment and cardiometabolic care. Their clinical benefits can be substantial, but weight loss can include lean mass as well as fat mass.
That makes physical activity more than a wellness add-on. Exercise, resistance training and protein intake are part of protecting strength, function and long-term health while weight is falling.
The industry angle is direct: obesity-care platforms, insurers, digital therapeutics and employers cannot treat medication adherence as the whole outcome. If patients move less during treatment, programmes may need explicit strength and activity support rather than assuming weight loss automatically improves movement.
Clinical caution: This article summarises conference-reported research and is not medical advice. People taking GLP-1 medications should discuss exercise, nutrition and muscle preservation with qualified clinicians.
Why It Matters
GLP-1 care is becoming a long-term health-system workflow, not just a prescription. Wearable evidence of reduced movement suggests programmes need to protect function and muscle, not only lower weight.
What to Watch
Watch whether obesity clinics, digital health vendors and payers build structured exercise and resistance-training support into GLP-1 treatment pathways.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
GLP-1ObesityWearablesExercise